-
The efficacy of statins in preventing cardiovascular events is well known, but approximately 10% of patients will develop elevations in liver function tests (LFTs).
-
This paper analyzes data from the national icd registry, which tracks ICD implantations for the primary prevention of sudden death in the United States.
-
The results of this well-done study suggest that a specific formulation of echinacea may offer modest benefit to people with the common cold, but that such benefit is statistically, and likely clinically, insignificant. Data from the trial relating to physician-patient interaction and clinical response have yet to be published.
-
Findings of this ground-breaking randomized controlled trial suggest that patients with irritable bowel syndrome who receive treatment with placebo tablets, and who are fully aware that they are taking a placebo, have significantly greater relief of symptoms compared with patients who receive no treatment at all. Accessing the placebo effect may not require deception at all.
-
-
Glucosamine sulfate continues to grow in popularity as a treatment for osteoarthritis. Global sales reached almost $2 billion in 2008, an increase of 60 percent over the previous five years.
-
An evaluation of medical research by the IOM establishes new RDAs for vitamin D (600-800 IU) and calcium (700-1300 milligrams).
-
Marine n-3 PUFAs act as pleiotropic agents on the cardiovascular system with a diverse range of effects most of which are beneficial for patients with known cardiovascular disease and possibly, they may even have beneficial effects with regard to the primary prevention of cardiovascular disease.
-
Clinicians should consider prescribing levothyroxine at bedtime since this study demonstrates significantly improved thyroid hormone levels compared to morning intake.
-
It seems reasonable to assume that atorva-statin has some anti-ischemic properties, based on the strong correlation between subjective angina reduction and reduction in objective ischemia demonstrated on AECG monitoring. However, there was no incremental benefit to the combination of atorvastatin and amlodipine.
